1 giotensin-converting enzyme (ACE) inhibitor, quinapril.

2 gebrium (1 mg/kg/day), or the ACE inhibitor, quinapril (30 mg/kg/day), for 20 weeks, and renal parame

3 e-blind, placebo-controlled study evaluating quinapril 80 mg/day, or the maximum tolerated dosage, in

4  tolerability of prolonged administration of quinapril, a long-acting angiotensin-converting enzyme i

5            Health status was not affected by quinapril, and one-half of the patients who believed the

6                      Those assigned to 40 mg quinapril continued that dose and those assigned to plac

7                                              Quinapril did not affect the occurrence of digital ulcer

8                            Administration of quinapril for up to 3 years had no demonstrable effects

9 f lcSSc as part of the baseline visit of the Quinapril in Scleroderma trial.

10                                              Quinapril inhibited PepT2-mediated currents in presence

11 mly assigned to one of two groups: 40 mg/day quinapril (n = 177) or placebo (n = 159) for 8 weeks.

12 th exacerbation of HAE-FXII during intake of quinapril or enalapril had no further HAE-FXII attacks a

13 -converting enzyme inhibition (ACE-I) (i.e., quinapril) prevents transient ischemia (exertional and s

14           Oocytes expressing PepT2 exhibited quinapril-sensitive outward currents.

15      In the absence of external substrate, a quinapril-sensitive proton inward current (proton leak)

16 CM hamsters, high-dose ACE inhibition alone (quinapril), started at 8 months and continued for 11 wee

17                                              Quinapril was not tolerated by one-fifth of the patients